Monitor for future filings regarding the commercialization agreement terms, milestone achievements, and any revenue generation from the partnership. The IP ownership structure favors Oncotelic for AI components while TechForce maintains rights to its robotics hardware.
Price Chart
Executive Summary
NightFood Holdings (NGTF) subsidiary TechForce Robotics entered a joint development agreement with Oncotelic Therapeutics to create AI-powered, GMP-compliant robotic systems for pharmaceutical manufacturing. The collaboration combines TechForce's robotics expertise with Oncotelic's AI-driven pharmaceutical platform technology, with Oncotelic retaining exclusive ownership of all AI-related intellectual property.
Key Financial Metrics
Key Facts
- TechForce Robotics (NGTF) and Oncotelic Therapeutics will jointly develop AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing
- Oncotelic retains exclusive ownership of all AI-related intellectual property and improvements to its PDAOAI platform
- TechForce owns its robotic hardware developments, while jointly developed IP will be co-owned
- The agreement includes a 12-month exclusivity period for TechForce regarding joint IP in the pharmaceutical manufacturing industry
- A separate commercialization and licensing agreement will be negotiated prior to first commercial sale
Financial Impact
Undisclosed funding amounts with milestone payments based on achievement
Risk Factors
- Uncertain commercial success of the developed robotic systems
- Potential delays in development milestones
- Dependence on successful negotiation of future commercialization terms
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015242 |
| Exhibit: ex99-1.htm | 0001493152-26-015242 |
| Document: form8-k.htm | 0001493152-26-015242 |
| Document: 0001493152-26-015242-index-headers.html | 0001493152-26-015242 |
| Document: 0001493152-26-015242-index.html | 0001493152-26-015242 |
| Document: 0001493152-26-015242.txt | 0001493152-26-015242 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $3.16 $3.14 | ▼ −0.63% | ▼ −0.11% | $3.14 (−0.63%) |
Oct 21, 2026 5d ago | 8-K | $2.88 $3.16 | ▲ +9.72% | ▲ +10.90% | $3.14 (+9.03%) |
Oct 20, 2026 6d ago | 8-K | $3.25 $2.88 | ▼ −11.38% | ▼ −11.91% | $3.14 (−3.38%) |
Aug 21, 2026 9w ago | 3 | $0.0358 $0.0314 | ▼ −12.29% | ▼ −12.61% | $3.14 (+8670.95%) |
Aug 14, 2026 10w ago | 8-K | $0.0229 $0.0260 | ▲ +13.54% | ▲ +14.01% | $3.14 (+13611.79%) |
Apr 16, 2026 27w ago | 8-K | $0.0280 $0.0269 | ▼ −3.93% | ▼ −5.14% | $3.14 (+11114.29%) |
Apr 6, 2026 29w ago | 8-K | $0.0294 $0.0292 | ▼ −0.68% | ▼ −0.74% | $3.14 (+10580.27%) |
Mar 4, 2026 33w ago | EFFECT | $0.0399 $0.0400 | ▲ +0.25% | ▲ +0.82% | $3.14 (+7769.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers